Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 1-22 , July 2008

Brugada Syndrome

References 

  1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–1396
  2. Ferracci A, Fromer M, Schlapfer J, et al. Primary ventricular fibrillation and early recurrence: apropos of a case of association of right bundle branch block and persistent ST segment elevation. Arch Mal Coeur Vaiss. 1994;87:1359–1362
  3. Proclemer A, Facchin D, Feruglio GA, et al. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: A new arrhythmia syndrome? A clinical case report. G Ital Cardiol. 1993;23:1211–1218
  4. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol. 1997;8:325–331
  5. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97:457–460
  6. Alings M, Wilde A. “Brugada” syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999;99:666–673
  7. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation. 2000;102:2509–2515
  8. Brugada P, Brugada R, Brugada J. Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V1 to V3 and sudden death. Eur Heart J. 2000;21:321–326
  9. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–296
  10. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85:803–809
  11. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–1666
  12. Rook MB, Bezzina Alshinawi C, Groenewegen WA, et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res. 1999;44:507–517
  13. Deschênes I, Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res. 2000;46:55–65
  14. Wilde AAM, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J. 2002;23:1648–1654
  15. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the Second Consensus Conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659–670
  16. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol. 2006;29:1130–1159
  17. Miyasaka Y, Tsuji H, Yamada K, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol. 2001;38:771–774
  18. Donohue D, Tehrani F, Jamehdor R, et al. The prevalence of Brugada ECG in adult patients in a large university hospital in the western United States. Am Heart Hosp J. 2008;6:48–50
  19. Hermida JS, Lemoine JL, Aoun FB, et al. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol. 2000;86:91–94
  20. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet. 2002;11:337–345
  21. Schulze-Bahr E, Eckardt L, Paul M, et al. Molecular genetics of the Brugada syndrome. In:  Antzelevitch C,  Brugada P editor. The Brugada Syndrome: from Bench to Bedside. 1st ed.. Blackwell Publishing; 2005;p. 42–51
  22. Vatta M, Dumaine R, Antzelevitch C, et al. Novel mutations in domain I of SCN5A cause Brugada syndrome. Mol Genet Metab. 2002;75:317–324
  23. Pfahnl AE, Viswanathan PC, Weiss R, et al. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm. 2007;4:46–53
  24. Casini S, Tan HL, Bhuiyan ZA, et al. Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation. Cardiovasc Res. 2007;76:418–429
  25. Cordeiro JM, Barajas-Martinez H, Hong K, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation. 2006;114:2026–2033
  26. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat. 2003;2:651–652
  27. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation. 2002;105:707–713
  28. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007;116:2260–2268
  29. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115:442–449
  30. Viswanathan PC, Benson DW, Balser JR. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest. 2003;111:341–346
  31. Poelzing S, Forleo C, Samodell M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation. 2006;114:368–376
  32. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res. 1988;62:116–126
  33. Kurita T, Shimizu W, Inagaki M, et al. The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol. 2002;40:330–334
  34. Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med. 2005;2:408–414
  35. Fish J, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm. 2004;1:210–217
  36. Litovsky SH, Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res. 1990;67:615–627
  37. Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061–1070
  38. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–515
  39. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731–1737
  40. Di Diego JM, Sun ZQ, Antzelevitch C. I(to) and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol. 1996;271(2 Pt 2):H548–H561
  41. Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation. 2002;106:2004–2011
  42. Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation. 2002;105:73–78
  43. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–1347
  44. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003;108:3092–3096
  45. Eckardt L, Probst V, Smits JPP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation. 2005;111:257–263
  46. Benito B, Arzamendi D, Porres J, et al. Seguimiento a largo plazo de los pacientes con sindrome de Brugada. Estudio multicentrico de los factores de mal pronostico. 2007;Congreso de las Enfermedades Cardiovasculares de la SEC 2007 Ref Type: Abstract
  47. Eckardt L, Kirchhof P, Loh P, et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association?. J Cardiovasc Electrophysiol. 2001;12:680–685
  48. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol. 2002;40:1437–1444
  49. Benito B, Brugada J. Recurrent syncope: an unusual presentation of Brugada syndrome. Nat Clin Pract Cardiovasc Med. 2006;3:573–577
  50. Makita N, Sumitomo N, Watanabe I, et al. Novel SCN5A mutation (Q55X) associated with age-dependent expression of Brugada syndrome presenting as neurally mediated syncope. Heart Rhythm. 2007;4:516–519
  51. Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J. 1999;20:465–470
  52. Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–706
  53. Kies P, Wichter T, Schafers M, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation. 2004;110:3017–3022
  54. Eckardt L. Gender differences in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:422–424
  55. Gehi A, Duong T, Metz L, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577–583
  56. Matsuo K, Akahoshi M, Seto S, et al. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin Electrophysiol. 2003;26:1551–1553
  57. Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender difference—role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:415–421
  58. Bai CX, Kurokawa J, Tamagawa M, et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112:1701–1710
  59. Song M, Helguera G, Eghbali M, et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem. 2001;276:31883–31890
  60. Probst V, Denjoy I, MeregalIi PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation. 2007;115:2042–2048
  61. Benito B, Sarkozy A, Berne P, et al. Características clínicas y pronóstico del síndrome de Brugada en la población pediátrica. 2007;Congreso de las Enfermedades Cardiovasculares de la SEC 2007 Ref Type: Abstract
  62. Veltmann C, Schimpf R, Echternach C, et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J. 2006;27:2544–2552
  63. Wilde AA. Spontaneous electrocardiographic fluctuations in Brugada syndrome: does it matter?. Eur Heart J. 2006;27:2493–2494
  64. Extramiana F, Seitz J, Maison-Blanche P, et al. Quantitative assessment of ST segment elevation in Brugada patients. Heart Rhythm. 2006;3:1175–1181
  65. Tatsumi H, Takagi M, Nakagawa E, et al. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol. 2006;17:705–711
  66. Mizumaki K, Fujiki A, Tsuneda T, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2004;15:667–673
  67. Shimizu W. Gender difference and drug challenge in Brugada syndrome. J Cardiovasc Electrophysiol. 2004;15:70–71
  68. Gonzalez Rebollo JM, Hernandez MA, Garcia A, et al. Recurrent ventricular fibrillation during a febrile illness in a patient with the Brugada syndrome. Rev Esp Cardiol. 2000;53:755–757
  69. Porres JM, Brugada J, Urbistondo V, et al. Fever unmasking the Brugada syndrome. Pacing Clin Electrophysiol. 2002;25:1646–1648
  70. Pitzalis MV, Anaclerio M, Iacoviello M, et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol. 2003;42:1632–1637
  71. Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006;47:1828–1834
  72. Babai Bigi MA, Aslani A, Shahrzad S. aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm. 2007;4:1009–1012
  73. Fish JM, Antzelevitch C. Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol. 2008;19:301–308
  74. Tada T, Kusano KF, Nagase S, et al. The relationship between the magnitude of T wave alternans and amplitude of the corresponding T wave in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2008;
  75. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001;104:3081–3086
  76. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A–related patients. J Am Coll Cardiol. 2002;40:350–356
  77. Yokokawa M, Noda T, Okamura H, et al. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the SCN5A-positive probands and the SCN5A-negative probands. Am J Cardiol. 2007;100:649–655
  78. Junttila MJ, Brugada P, Hong K, et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol. 2007;
  79. Hong K, Brugada J, Oliva A, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation. 2004;110:3023–3027
  80. Meregalli PG, Ruijter JM, Hofman N, et al. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:857–864
  81. Priori SG, Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. Circulation. 2005;112:279–292
  82. Wolpert C, Echternach C, Veltmann C, et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm. 2005;2:254–260
  83. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J. 2001;22:2290–2296
  84. Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol. 2000;11:396–404
  85. Miyamoto K, Yokokawa M, Tanaka K, et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol. 2007;99:53–57
  86. Brugada P, Brugada R, Brugada J, et al. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. Circulation. 2005;112:279–292
  87. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006;114:2317–2324
  88. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J. 2007;28:334–344
  89. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–373
  90. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  91. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004;43:1853–1860
  92. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004;27(6 Pt 1):821–823
  93. Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007;4:695–700
  94. Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2002;13:698–701
  95. Abud A, Bagattin D, Goyeneche R, et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:210–212

PII: S0033-0620(08)00038-8

doi: 10.1016/j.pcad.2008.05.002

Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 1-22 , July 2008

Article Tools

* Image Usage & Resolution